Plant-Based Protein Expression Coming of Age

In R&D by Freya Smale4 Comments

download, plant-based protein expression, vaccine production

Can plant-based protein expression systems turn into a leading industrial technology? What do you think? Tell us by commenting below.

Dr John Butler-Ransohoff, Project Manager for Plant-made Pharmaceuticals, Bayer Innovations joined us at the World Vaccine Congress in Washington DC 2012 to answer this question. The advantages of plant- based expression include: speed, versatility and scalability, reduced cost of production, and in some cases, improved product quality.

The 2009 Flu pandemic showed us that transient plant-based expression may be best suited for pandemic vaccines. Producing countries use vaccines first and foremost to protect their own citizens, demonstrating the need for a "warm-base" production capacity with fast reaction times. The speed, versatility and scalability of plant-based expression could answer this need.

The most important aspect of vaccine production is safety. Plants derived proteins are safer in certain cases as plants do not harbour human pathogens, reducing the risk from the production host. Reduced risk from vector is also possible as plant-viral vectors do not replicate in human tissue.

Why not download the full presentation to find out: Can plant cell-lines grow into the industry leaders?

  • Why plant cell-lines are ideal for vaccine production and can address the problems of a pandemic
  • Can the limiting factor of limited regulatory experience of plant cell-lines be overcome to allow the further developments?
  • Understanding that the regulatory viral concerns surrounding plant cell-lines have less associated cost in DSP than mammalian cells

Download the full presentation here!

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Comments

  1. Ed Rybicki

    I am waiting impatiently for the clinical trial results of the plant-made pandemic influenza vaccines sponsored by DARPA – because if those don’t convince the pharma community that plants have a future as a production platform for high-value recombinant proteins, then nothing will!!

  2. Freya

    Thanks for commenting. Hopefully the results from the plant-made pandemic influenza vaccines sponsored by DARPA will have a significant effect on changing the community’s views.

    For those interested in finding out more, the following link provides more general information on the programme Ed is talking about, but sadly no clinical trial results as of yet! http://www.darpa.mil/NewsEvents/Releases/2012/07/25.aspx

    Any more information I can find, or any more presentations related to this topic, I will post. I know that we have some interesting speakers attending the World Vaccine Congress in Washington 2013, who may shed some more light on the future of using plant-based vaccine products.

  3. Marva Loblack

    I am waiting impatiently for the clinical trial results of the plant-made pandemic influenza vaccines sponsored by DARPA as well. Personally I find this technology to be quite expensive so I am not sure about this reduce cost that is spoken about here. With few companies offering this technology it is quite expensive. Scaling up is also an issue.

  4. Author
    freya

    Hi Marva,

    I just posted a discussion on LinkedIn, which I think would be of interest. The discussion: Is the future of vaccines in plant-based production? You can find it on our LinkedIn group, just click on the Blue “IN” box link on the right of this post.

    I look forward to hearing more of your views on this subject.

Leave a Comment

Current ye@r *